Ahead of the launch, the firm has taken steps to amplify its production capacities to ensure adequate supply, and believes ...

Hims & Hers Health’s stock booked record losses Monday after Novo Nordisk, maker of the weight-loss drug Wegovy, said it was ...

Semaglutide improved time spent in glycemic range, time below rate and reduced body weight with low rates of hypoglycemia ...

The fortune of the San Francisco-based telehealth company’s cofounder and chief executive, Andrew Dudum, crumbled by more ...

Amgen's late-stage weight-loss drug MariTide is getting ready to enter the final stages of testing as the company enrolls its ...

Once-monthly maridebart cafraglutide resulted to significant weight loss at 1 year among adults with obesity, regardless of ...

Amycretin, a new weight-loss treatment from Novo Nordisk, combines two hunger hormones, helping participants lose nearly ...

Hims & Hers Health shares tumbled nearly 35% Monday after Novo Nordisk said it is pulling out of its partnership with the ...

The companies engaged in an increasingly heated war of words on Monday following the drugmaker's decision to end a collaboration.

Novo Nordisk unveiled its latest data for a weight-loss drug candidate, but shares of the maker of Wegovy and Ozempic tumbled ...

Novo Nordisk A/S scrapped a partnership with Hims & Hers Health Inc. after less than two months, saying the US company is ...

First, the stock has sliced through two support levels. Shares broke through their 50-day moving average on Monday for the ...